Literature DB >> 6449905

Tentative interpretive standards for disk susceptibility tests with moxalactam (LY127935).

A L Barry, C Thornsberry, R N Jones, E H Gerlach.   

Abstract

Moxalactam (LY127935; 6059-S) is a new beta-lactam antibiotic. We propose tentative zone standards for agar diffusion susceptibility tests with 30-microgram disks. The final selection of minimal inhibitory concentration breakpoints for definition of resistant and susceptible categories must await clinical experience with this drug. Some of the clinical questions to be answered are defined. A moderately susceptible (intermediate) category is proposed for those strains with minimal inhibitory concentrations of 16 or 32 microgram/ml (zones 15 to 22 mm in diameter). Strains with minimal inhibitory concentrations of greater than or equal to 64 microgram/ml are considered resistant, and those with minimal inhibitory concentrations of less than or equal to 8 microgram/ml are considered susceptible. Tests with 30-microgram disks did not satisfactorily separate strains with minimal inhibitory concentrations of 8 microgram/ml from strains requiring < 2 microgram/ml for inhibition, because the regression line became parabolic at concentrations of 2 microgram/ml and below. However, the disk tests were satisfactory for categorizing isolates into the above-described susceptible, moderately susceptible (intermediate), and resistant categories.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6449905      PMCID: PMC284081          DOI: 10.1128/AAC.18.5.716

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  9 in total

1.  Susceptibility tests of anaerobic bacteria: statistical and clinical considerations.

Authors:  C M Metzler; R M DeHaan
Journal:  J Infect Dis       Date:  1974-12       Impact factor: 5.226

2.  Cefaclor and cefatrizine, new investigational orally administered cephalosporins. In-vitro collaborative evaluation against clinical bacterial isolates and comparison with related antimicrobics.

Authors:  R N Jones; P C Fuchs; C Thornsberry; A L Barry; T L Gavan; E H Gerlach
Journal:  Am J Clin Pathol       Date:  1979-10       Impact factor: 2.493

3.  Antibacterial activity of a new 1-oxa cephalosporin compared with that of other beta-lactam compounds.

Authors:  H C Neu; N Aswapokee; K P Fu; P Aswapokee
Journal:  Antimicrob Agents Chemother       Date:  1979-08       Impact factor: 5.191

4.  LY-127935: a novel beta-lactam antibiotic with unusual antibacterial activity.

Authors:  G M Trager; G W White; V M Zimelis; A P Panwalker
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

5.  Moxalactam (LY127935), a new semisynthetic 1-oxa-beta-lactam antibiotic with remarkable antimicrobial activity: in vitro comparison with cefamandole and tobramycin.

Authors:  R N Jones; P C Fuchs; H M Sommers; T L Gavan; A L Barry; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1980-04       Impact factor: 5.191

6.  LY127935, a new beta-lactam antibiotic, versus Proteus, Klebsiella, Serratia, and Pseudomonas.

Authors:  D J Flournoy; F A Perryman
Journal:  Antimicrob Agents Chemother       Date:  1979-11       Impact factor: 5.191

7.  LY127935, a novel oxa-beta-lactam: an in vitro comparison with other beta-lactam antibiotics.

Authors:  R Wise; J M Andrews; K A Bedford
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

8.  Piperacillin susceptibility tests by the single-disk agar diffusion technique.

Authors:  A L Barry; C Thornsberry; R E Badal; C N Baker; R N Jones; E H Gerlach
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

9.  In vitro activity of LY127935.

Authors:  M Barza; F P Tally; N V Jacobus; S L Gorbach
Journal:  Antimicrob Agents Chemother       Date:  1979-09       Impact factor: 5.191

  9 in total
  12 in total

1.  [Resistance of clinical isolates of some Enterobacteriaceae as well as Pseudomonas aeruginosa, Staphylococcus aureus, and Streptococcus faecalis to chemotherapeutic agents. Results of an inter-regional cooperative study for the years 1980 and 1981].

Authors:  B Wiedemann
Journal:  Infection       Date:  1982 Sep-Oct       Impact factor: 3.553

2.  Cefotetan, a new cephamycin: comparison of in vitro antimicrobial activity with other cephems, beta-lactamase stability, and preliminary recommendations for disk diffusion testing.

Authors:  L W Ayers; R N Jones; A L Barry; C Thornsberry; P C Fuchs; T L Gavan; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1982-11       Impact factor: 5.191

3.  Sensitivity of 341 non-fermentative gram-negative bacteria to seven beta-lactam antibiotics.

Authors:  P C Appelbaum; J Tamim; J Stavitz; R C Aber; G A Pankuch
Journal:  Eur J Clin Microbiol       Date:  1982-06       Impact factor: 3.267

4.  Quality control of moxalactam susceptibility disks.

Authors:  A L Barry; D A Preston; R N Jones; T L Gavan; C Thornsberry
Journal:  J Clin Microbiol       Date:  1983-06       Impact factor: 5.948

5.  Cefmenoxime (SCE-1365), a new cephalosporin: in vitro activity, comparison with other antimicrobial agents, beta-lactamase stability, and disk diffusion testing with tentative interpretive criteria.

Authors:  P C Fuchs; R N Jones; C Thornsberry; A L Barry; E H Gerlach; H M Sommers
Journal:  Antimicrob Agents Chemother       Date:  1981-12       Impact factor: 5.191

6.  False-susceptible results from the MS-2 system used for testing resistant Pseudomonas aeruginosa against two third-generation cephalosporins, moxalactam and cefotaxime.

Authors:  L L Stone; D L Jungkind
Journal:  J Clin Microbiol       Date:  1983-08       Impact factor: 5.948

Review 7.  Moxalactam (latamoxef). A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  A A Carmine; R N Brogden; R C Heel; J A Romankiewicz; T M Speight; G S Avery
Journal:  Drugs       Date:  1983-10       Impact factor: 9.546

8.  Cefoperazone disk diffusion susceptibility test: confirmation of the tentative interpretive criteria, Pseudomonas aeruginosa cross-resistance, and determination of quality control performance limits.

Authors:  R N Jones; T L Gavan; A L Barry; C Thornsberry; D L Gibbs
Journal:  J Clin Microbiol       Date:  1982-05       Impact factor: 5.948

9.  Randomized comparative study of moxalactam and cefazolin in the treatment of acute urinary tract infections in adults.

Authors:  A S Lea; A W Sudan; B A Wood; L O Gentry
Journal:  Antimicrob Agents Chemother       Date:  1982-07       Impact factor: 5.191

10.  Comparative in vitro activities of N-formimidoyl thienamycin and moxalactam against nonfermentative aerobic gram-negative rods.

Authors:  E D O'Donnell; E H Freimer; G L Gilardi; R Raeder
Journal:  Antimicrob Agents Chemother       Date:  1982-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.